Verastem, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Verastem, Inc. (VSTM) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $2.90 million as of 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-04
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.90M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.76M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.34M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.45M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $2.90M 10-K · filed 2026-03-04 |
| 2024-12-31 | $2.76M 10-K · filed 2026-03-04 |
| 2023-12-31 | $3.34M 10-K · filed 2025-03-20 |
| 2022-12-31 | $3.45M 10-K · filed 2024-03-14 |
| 2021-12-31 | $4.20M 10-K · filed 2023-03-14 |
| 2020-12-31 | $4.04M 10-K · filed 2022-03-28 |
| 2019-12-31 | $4.45M 10-K · filed 2021-03-18 |
| 2018-12-31 | $3.76M 10-K · filed 2020-03-11 |
| 2017-12-31 | $2.56M 10-K · filed 2019-03-12 |
| 2016-12-31 | $3.08M 10-K · filed 2018-03-13 |
| 2015-12-31 | $4.40M 10-K · filed 2017-03-23 |
| 2014-12-31 | $726.00K 10-K · filed 2016-03-03 |
| 2013-12-31 | $511.00K 10-K · filed 2015-03-10 |
| 2012-12-31 | $797.00K 10-K · filed 2014-03-06 |
| 2011-12-31 | $82.00K 10-K · filed 2013-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |